Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 Photo by Dan Dennis on Unsplash O?n October 31, Morgan? Stanley upgraded Novartis AG (NYSE:NVS) to? Overw?eight from E?qu?al Weight, raising its? price? target to CHF 110? f?rom CHF 108, as reported by The Fly. The firm cited an attractive valuation following the recent market sell-off. The analyst noted tha?t Novartis is improving its portfolio mix ahead of the u?pcoming? Rhapsido launch. While Morgan Stanley expects mo?dest growth in 2026, it anticipates acceleration starting in 2027. ?In t?he third q?uarte?r of 2025, Novartis AG (NYSE:NVS) re?ported r?evenue of $13.9 billion, u?p 8% fr?om the same peri?od last year?. Free c?ash flow for Q3 r?ea?ch?ed $6.2? billion?, a 4% increase?, supporte?d? by str?onger net cash from operating a?cti?vities.? Opera?ting i?ncome rose? 2?4% to $4.5? billion, driv?en? by higher sales and lower impairments, parti?ally offse?t by increased R&D spending. Net inc
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NYSE:NVS) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novartis (NYSE:NVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Janux dives as gaps in prostate cancer study data worry investors [Yahoo! Finance Canada]Yahoo! Finance Canada
- Progress In Fight Against Malaria, As New Treatment Shows Promise [Forbes]Forbes
- Novartis (NYSE:NVS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NVS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website